glp-1 blood clot medicines may cut clot-related risks in chronically inflamed patients Can GLP-1 Medications Be Considered

The recommended initial dose for semaglutide is 0.25 mg/day, which is increased to 0.5 mg after four weeks, followed by another four weeks, until the maintenance dose (0.5 mg or 1.0 mg) is reached [39]

Late breaking at #ADA2023: In this 36-week, randomized trial, daily oral orforglipron was associated with clinically significant weight reduction, with efficacy and safety similar to those of injectable GLP-1 receptor agonists

Park, H.K

Lauren Kelley-Chew & Dr

It is believed to inhibit the enzyme tyrosinase, which plays a key role in melanin production

One such study with semaglutide (generic drug name for Wegovy) found that on discontinuation of the medication, patients regained about two-thirds of their prior weight loss in just a year